MGTX on Nasdaq

MeiraGTx Holdings plc

We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with bluebird bio, 4D Molecular Therapeutics, Inc. or Autolus Therapeutics, or pick any stock.

  • TickerMGTX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersNew York, New York1
  • Business address655 Third Avenue, Suite 1115, New York, Ny 100172
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities. We have two viral vector production facilities for good manufacturing practices, or GMP, internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for Investigational New Drug application (IND) through commercial supply. In addition, we have developed a proprietary manufacturing platform with industry-leading yield and quality aspec…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-130.2%Operating margin4
-140.3%Net margin4
144.6%Revenue growth, 20254
-$50.2MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License brought in 92% of the revenue MeiraGTx Holdings plc broke down this way in fiscal 2025.

  1. License$75.0M492%
  2. Related Party Service Revenue$6.4M48%down 81% from 2024
Products and services by year
Products and services20242025
License$75.0M
Related Party Service Revenue$33.3M$6.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development91¢$129.6M
  • Interest9¢$12.2M

Out of $81.4M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$81.4M in 2025+512% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $13.3M$13.3M20192020: $15.6M$15.6M2020+17%2021: $37.7M$37.7M2021+142%2022: $15.9M$15.9M2022−58%2023: $14.0M$14.0M2023−12%2024: $33.3M$33.3M2024+137%2025: $81.4M$81.4M2025+145%
Operating income567984-$106.0M in 2025+82% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$58.3M-$58.3M20192020: -$62.6M-$62.6M2020+7%2021: -$72.8M-$72.8M2021+16%2022: -$116.4M-$116.4M2022+60%2023: -$137.1M-$137.1M2023+18%2024: -$164.2M-$164.2M2024+20%2025: -$106.0M-$106.0M2025−35%
Net income567984-$114.2M in 2025+109% since 2019
-$150.0M-$100.0M-$50.0M02019: -$54.7M-$54.7M20192020: -$58.0M-$58.0M2020+6%2021: -$79.6M-$79.6M2021+37%2022: -$129.6M-$129.6M2022+63%2023: -$84.0M-$84.0M2023−35%2024: -$147.8M-$147.8M2024+76%2025: -$114.2M-$114.2M2025−23%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$81.4M$33.3M
Cost of service revenue - related party$4.8M$23.8M
General and administrative$52.9M$54.2M
Research and development$129.6M$119.5M
Total operating expenses$187.4M$197.5M
Loss from operations-$106.0M-$164.2M
Foreign currency gain (loss)$2.1M-$2.9M
Interest income$1.8M$4.1M
Interest expense-$12.2M-$13.3M
Gain on sale of nonfinancial assets$28.4M
Net loss-$114.2M-$147.8M
Foreign currency translation gain (loss)$6.1M-$2.3M
Comprehensive loss-$108.1M-$150.1M
Net loss-$114.2M-$147.8M
Basic net loss per ordinary share-$1.42-$2.12
Diluted net loss per ordinary share-$1.42-$2.12
Weighted-average number of ordinary shares outstanding, basic80.4M shares69.8M shares
Weighted-average number of ordinary shares outstanding, diluted80.4M shares69.8M shares

Compare MeiraGTx Holdings plc with another company

Leadership

Who has led MeiraGTx Holdings plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alexandria Forbes2018–now

President

  1. Alexandria Forbes2018–now

Chief financial officer

  1. Katherine Breedis2018–2019
  2. Richard Giroux2020–now

Chief operating officer

  1. Richard Giroux2018–now
20202025
Board members and other officers (17)

Timeline

  1. Jun 8, 2018New chief executive Alexandria Forbes becomes CEO12

Filings

306 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 159 insider forms, 26 large holders, 51 other. The latest 20:

  1. Oct 6, 2026144 EDGAR
  2. Oct 6, 20264 EDGAR
  3. Sep 24, 20264 EDGAR
  4. Sep 24, 20263 EDGAR
  5. Sep 23, 20268-K EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 18, 2026144 EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 13, 2026S-8 EDGAR
  10. Aug 13, 202610-Q EDGAR
  11. Aug 13, 20268-K EDGAR
  12. Jul 21, 20264 EDGAR
  13. Jul 21, 2026144 EDGAR
  14. Jul 7, 2026144 EDGAR
  15. Jul 7, 20264 EDGAR
  16. Jul 7, 20268-K EDGAR
  17. Jun 29, 20264 EDGAR
  18. Jun 29, 20264 EDGAR
  19. Jun 29, 20264 EDGAR
  20. Jun 29, 20264 EDGAR

The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 4 buys and 22 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 18, 2026Forbes AlexandriaPRESIDENT & CEOSale62,000$13.86$859.3KForm 4
Jul 21, 2026Giroux RichardCFO & COOSale56,000$12.51$700.6KForm 4
Jul 7, 2026Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGYSale27,659$14.80$409.5KForm 4
May 19, 2026Forbes AlexandriaPRESIDENT & CEOSale62,000$9.17$568.5KForm 4
Apr 21, 2026Giroux RichardCFO & COOSale56,000$10.22$572.3KForm 4
Apr 7, 2026Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGYSale27,661$9.36$258.9KForm 4
Mar 24, 2026Forbes AlexandriaPRESIDENT & CEOSale62,000$7.41$459.4KForm 4
Oct 21, 2025Giroux RichardCFO & COOSale24,000$8.87$212.9KForm 4
Oct 7, 2025Forbes AlexandriaPRESIDENT & CEOSale47,500$8.39$398.5KForm 4
Jul 22, 2025Giroux RichardCFO & COOSale24,000$8.52$204.5KForm 4
Jul 8, 2025Forbes AlexandriaPRESIDENT & CEOSale47,500$7.97$378.6KForm 4
Apr 22, 2025Giroux RichardCFO & COOSale24,000$6.00$144.0KForm 4
Apr 8, 2025Forbes AlexandriaPRESIDENT & CEOSale47,500$5.34$253.7KForm 4
Jan 21, 2025Giroux RichardCFO & COOSale24,000$6.29$151.0KForm 4
Jan 8, 2025Forbes AlexandriaPRESIDENT & CEOSale11,661$6.30$73.5KForm 4
Jan 7, 2025Forbes AlexandriaPRESIDENT & CEOSale35,839$6.47$231.9KForm 4
Aug 12, 2024EDELMAN JOSEPHDirectorBuy1,250,000$4.00$5.0MForm 4
May 5, 2023PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirectorBuy4,347,826$5.75$25.0MForm 4
Jun 3, 2022Zeldin Robert KCHIEF MEDICAL OFFICERBuy5,000$7.90$39.5KForm 4
May 25, 2022Wollin Robert JGENERAL COUNSEL AND SECRETARYBuy1,000$7.94$7.9KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37